Abstract:Objective To investigate the synergetic role in inducing apoptosis of osteosarcoma cell(MG-63)when tumor necrosis factor-related apoptosis inducing ligand(TRAIL)combined with interferon(IFN)-γ.to explore the potential mechanism of synergistic antitumor activity,and to observe the toxicity of TRAIL combined with IFN-γin fibroblast.Methods The mor- pholngy was observed with inverted phase contrast microscope and electronic microscope after MC-63 was treated by TRATL, IFN-γ,and TRAIL combined with IFN-γRespectively inhibition rate and apoptosis rate was assessed by methyl thiazolyl tet- razolizm(MTT)assay and flow cytometer(FCM).After MG-63 was intervened by IFN-γ.the expression of TRAIL receptors was detected by Reverse Transcription-Polymerase Chain Reaction(RT-PCR).The toxicity of TRAIL combined with IFN-γin fihro- blast was evaluated by MTT assay.Results The growth activity of MG-63 was weakened after it was intervened by TRAIL com- bined with IFN-γ.When it was treated by IFN-γfor 24 hours,then combined with TRAIL,it showed the lowest activity.The Electronic microscope could reveal the apoptosis characteristic changes.The inhibition rate of MG-63 increased obviously by combi- ning TRAIL and IFN-γ,comparing with administration of TRAIL alone,and the difference was statistically significant(P0.01).The apoptosis rate of MG-63 increased obviously by combining TRAIL and IFN-γ,and the difference was significant(P0.01).The expression of death receptor(DR)4 was increased significantly(P0.01)when MG-63 had been treated with IFN-γfor 24 hours.The toxicity of TRAIL combined with IFN-γin fibroblast was not increased(P0.05).Conclusions IFN-γhad synergetic role in the apoptosis effect induced by TRAIL in MG-63.Up-regulating DR4 might he one of the reasons for synergetic antitumor activity.The risk of toxicity in fibroblast was not raised when TRAIL combined with IFN-γ.

Fusion of an EGFR-antagonistic affibody enhances the anti-tumor effect of TRAIL to EGFR positive tumors

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells

Improving Targeted Delivery and Antitumor Efficacy with Engineered Tumor Necrosis Factor-Related Apoptosis Ligand-Affibody Fusion Protein

Improving Targeted Delivery and Antitumor Efficacy of TRAIL Through Fusion with a B7H3-Antagonistic Affibody

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

Enhancement of Anti-Tumor Properties of Trail by Targeted Delivery to the Tumor Neovasculature

Customizing a Tridomain TRAIL Variant to Achieve Active Tumor Homing and Endogenous Albumin-Controlled Release of the Molecular Machine in Vivo

Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle

Engineering and refolding of a novel trimeric fusion protein TRAIL-collagen XVIII NC1

Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities

Fused Hydrophobic Elastin-Like-Peptides (elp) Enhance Biological Activity of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail)

Optimizing Multistep Delivery of PEGylated Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand-Toxin Conjugates for Improved Antitumor Activities.

EGFR Inhibitors Sensitize Non-Small Cell Lung Cancer Cells to TRAIL-induced Apoptosis

Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo

An optimized antibody-single-chain TRAIL fusion protein for cancer therapy

Enhanced Apoptosis: TRAIL‐Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582) (adv. Healthcare Mater. 11/2021)

Trail-Armed Er Nanosomes Induce Drastically Enhanced Apoptosis In Resistant Tumor In Combination With The Antagonist Of Iaps (Azd5582)

Experimental Study on Apoptosis of Osteosarcoma Cell Induced by TRAIL Combined with IFN-γ

A novel tumor-homing TRAIL variant eradicates tumor xenografts of refractory colorectal cancer cells in combination with tumor cell-targeted photodynamic therapy

Molecular superglue-mediated higher-order assembly of TRAIL variants with superior apoptosis induction and antitumor activity